Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04183218 · ClinicalTrials.gov registry record
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
A clinical trial of Clinical Stage III Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Adenocarcinoma AJCC v8, sponsored by Mayo Clinic.
- Completed
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT04183218: Completed study of Clinical Stage III Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Adenocarcinoma AJCC v8, sponsored by Mayo Clinic.
NCT04183218 is a study of Clinical Stage III Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Adenocarcinoma AJCC v8 that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 105-participant average among 12 other Clinical Stage III Esophageal Adenocarcinoma AJCC v8 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04183218, a study of Clinical Stage III Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Adenocarcinoma AJCC v8, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.
Primary Outcome
Assessed as any cardiac event after registration, including electrophysiological changes as defined by the continuous insertable cardiac monitor (ICM); congestive heart failure (CHF); myocardial infarction; pericarditis or myocarditis; cardiac ablation or cardiac pacemaker; cardiac stent placement or any coronary procedure for coronary damage; or any cardiac event as defined by the patients' medical records or autopsy if done.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- RADIATION Radiation Therapy
- OTHER Chemoradiotherapy
- DEVICE Cardiac Event Monitor
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2024-05-02 |
What the finished NCT04183218 record still lists
NCT04183218 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 105-participant average among 12 other Clinical Stage III Esophageal Adenocarcinoma AJCC v8 trials with a reported enrollment target (77% lower).
The record links to 10 conditions, with Clinical Stage III Esophageal Adenocarcinoma AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04183218 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT04183218 about?
NCT04183218 is a clinical study titled "Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes". This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify card...
What is the current status of trial NCT04183218?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2019-09-23. Estimated completion is 2024-05-02.
What conditions does trial NCT04183218 study?
This clinical trial studies the following conditions: Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8.
What interventions are being tested in trial NCT04183218?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Radiation Therapy (RADIATION), Chemoradiotherapy (OTHER), Cardiac Event Monitor (DEVICE).
Who is sponsoring clinical trial NCT04183218?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04183218 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04183218's enrollment target sits among peer trials
24 9th of 12 higher than 3 of 12 other Clinical Stage III Esophageal Adenocarcinoma AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clinical Stage III Esophageal Adenocarcinoma AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RECRUITING · Phase 2
-
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RECRUITING · Phase 3
-
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
RECRUITING · Phase 3
-
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI